In addition, LRRK2 mutations can affect mitochondrial axonal transport, which in turn affects mitochondrial function and plays an important role in the pathogenesis of PD, but LRRK2 kinase inhibitors have not yet been able to rescue this defect (Hsieh et al., 2016; Jeong and Lee, 2020). This evidence concerns the gene LRRK2 and Parkinson disease.